Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IgPro20 maintenance therapy in CIDP
NL-OMON39905Phase 3Active, not recruiting
- Sponsor
- CSL Behring
- Start
- Jan 2013
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of polyvalent human immunoglobulin in chronic inflammatory demyelinating polyneuropathy (CIDP) (3 arms), sponsored by CSL Behring. Primary endpoint: Primary efficacy endpoint. Started Jan 2013; status: active, not recruiting.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NL-OMON39905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39905.